Piper Sandler Reaffirms “Overweight” Rating for InspireMD (NYSE:NSPR)

Piper Sandler restated their overweight rating on shares of InspireMD (NYSE:NSPR) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $4.50 target price on the stock.

Separately, StockNews.com began coverage on InspireMD in a report on Sunday, September 15th. They set a sell rating on the stock.

InspireMD Price Performance

InspireMD stock opened at $2.61 on Tuesday. The stock has a fifty day moving average price of $2.77 and a two-hundred day moving average price of $2.51. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.85. The firm has a market capitalization of $64.97 million, a P/E ratio of -3.46 and a beta of 0.90.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter last year, the business posted ($0.24) earnings per share. On average, equities research analysts predict that InspireMD will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. bought a new position in InspireMD, Inc. (NYSE:NSPR) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.